Tavneos

News

EMA advisors say CSL's Tavneos should be pulled from sale

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

News

Amgen baulks at FDA request to withdraw Tavneos

Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated vasculitis from the US market.

News

Bottle of Tavneos with two pills in front of it

EMA looks into 'data integrity' issue with Amgen's Tavneos

Concerns about efficacy data in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered a review in the EU.

News

CSL Vifor plans UK launch after NICE backs rare disease drug...

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavne

News

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.

EMA advisors say CSL's Tavneos should be pulled from sale

FDA points to liver injury with Amgen's Tavneos

Amgen baulks at FDA request to withdraw Tavneos

EMA looks into 'data integrity' issue with Amgen's Tavneos

CSL Vifor plans UK launch after NICE backs rare disease drug...

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Despite study bust, Vistagen still hopes to file anxiety dru...

Discover a new era of healthcare panel engagement: Grounded ...

Tavneos

Editor's Picks